MANA 512
Alternative Names: MANA-512Latest Information Update: 05 Apr 2021
At a glance
- Originator Mana Therapeutics
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 25 Mar 2021 MANA 512 is available for licensing as of 25 Mar 2021. https://www.manatherapeutics.com/collaborations
- 25 Mar 2021 Early research in Cancer in USA (Parenteral) (Mana Therapeutics pipeline, March 2021)